Assessment of Total, PTEN–, and AR-V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide
- 3 April 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Genitourinary Cancer
- Vol. 19 (5), e286-e298
- https://doi.org/10.1016/j.clgc.2021.03.021
Abstract
No abstract availableThis publication has 30 references indexed in Scilit:
- Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate CancerThe New England Journal of Medicine, 2020
- Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysisCritical Reviews in Oncology/Hematology, 2020
- Recent Global Patterns in Prostate Cancer Incidence and Mortality RatesEuropean Urology, 2019
- Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical TrialsJournal of Clinical Oncology, 2018
- Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL StudyEuropean Urology, 2016
- Enzalutamide: Development from bench to bedsideUrologic Oncology, 2015
- Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate CancerJournal of Clinical Oncology, 2015
- New perspectives in the therapy of castration resistant prostate cancer.Current Drug Targets, 2012
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyThe New England Journal of Medicine, 2012
- Sipuleucel-T for prostate cancer: the immunotherapy era has commenced.Expert Review of Anticancer Therapy, 2011